[A24-67] Vadadustat (anaemia associated with chronic kidney disease on dialysis) – Benefit assessment according to § 35a Social Code Book V
Last updated 22.11.2024
Project no.:A24-67
Commission:
Commission awarded on 30.05.2024 by the Federal Joint Committee (G-BA).Report type:
Dossier assessmentStatus:Commission completed
Department/Division:
Drug AssessmentTopic:
Kidneys and urinary system
Indication:
Adult patients with symptomatic anaemia associated with chronic kidney disease (CKD) who are on chronic maintenance dialysis
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A24-67_en
Federal Joint Committee (G-BA)
2024-11-22 A G-BA decision was published.